Le Lézard
Classified in: Health, Business
Subject: PSF

SCAN Alerts Members Affected by Southern California Wildfires How to Access Benefits

LONG BEACH, Calif., Aug. 10, 2018 /PRNewswire/ -- SCAN Health Plan® is alerting its members in Riverside and Orange Counties that they can and should access the medical care, supplies and prescription drugs they need during this emergency situation. SCAN covers out-of-area urgent and emergency care and will lift certain requirements so that members can refill or replace prescriptions and medically needed supplies.  Employees are standing by to help answer members' questions about access to their health plan benefits.


SCAN Health Plan is an HMO plan with a Medicare contract and a contract with the California Medi-Cal (Medicaid) program. Enrollment in SCAN Health Plan depends on contract renewal. As governed by the Centers for Medicare & Medicaid Services, member benefits vary by county.



These press releases may also interest you

at 17:30
A bioelectronic medicine device was effective in reducing pain and fatigue in patients with lupus, according to Feinstein Institute for Medical Research Professor Cynthia Aranow, MD, who will present pilot clinical trial results Tuesday at the...

at 15:00
SEATTLE, Oct. 20, 2018 /PRNewswire-PRWeb/ -- KitoTech Medical, a Seattle-based medical device company, announced today that it has entered into a national distribution agreement with North American Rescue LLC (NAR), a manufacturer and supplier of...

at 13:00
BioLineRx Ltd. , a clinical-stage biopharmaceutical company focused on oncology and immunology, today disclosed additional data from the in-depth analyses of biopsies of the dual combination arm of the Phase 2a COMBAT/KEYNOTE-202 study, evaluating...

at 10:30
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of CV Sciences, Inc. from June 19, 2017 through August 20, 2018, inclusive (the "Class Period"). The lawsuit...

at 09:41
TWi Biotechnology, Inc. (6610 TTO), a clinical stage biotechnology company focused on developing novel inhibitors of inflammasomes, today announced that it has enrolled the first patient in a phase 2 trial of AC-203 for the treatment of inherited...

at 09:04
The antibody CAN04 was well tolerated and 6 mg/kg is a safe dose Effects on biomarkers and 5 of 13 evaluable patients achieved stable disease 10 mg/kg currently investigated before start of phase IIa during Q4 2018Cantargia AB (publ) today presented...

News published on 10 august 2018 at 18:38 and distributed by: